Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mirtazapine

FDA-approved product (tablet, oral), marketed as Mirtazapine, Remeron, Remeron Soltab.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Mirtazapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Insomnia
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mirtazapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mirtazapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Adolescent Suicide Attempters (TASA)

    NCT00080158 · start 2004-03

    Registered record
    Registry ID
    NCT00080158
    Conditions
    Depression; Suicide, Attempted
    Interventions
    fluoxetine; sertraline; citalopram; escitalopram; bupropion; mirtazapine; venlafaxine; lithium; Cognitive Behavioral Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-03
    Completion
    2007-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Suicide, Attempted
    Interventionfluoxetine; sertraline; citalopram; escitalopram +5 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder

    NCT00385437 · start 2003-04

    Registered record
    Registry ID
    NCT00385437
    Conditions
    Depression; Excessive Daytime Sleepiness
    Interventions
    Driving Simulator Testing; Mirtazapine Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-04
    Completion
    2004-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Excessive Daytime Sleepiness
    InterventionDriving Simulator Testing; Mirtazapine Treatment
    PhasePhase 2
    Registry statusCompleted

  • Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

    NCT00817375 · start 2003-02

    Registered record
    Registry ID
    NCT00817375
    Conditions
    Depression; Adverse Reaction to Drug
    Interventions
    SSRI treated group; non-SSRI treated group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2003-02
    Completion
    2018-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Adverse Reaction to Drug
    InterventionSSRI treated group; non-SSRI treated group
    PhaseNot applicable
    Registry statusUnknown

  • Predict Antidepressant Responsiveness Using Pharmacogenomics

    NCT01228357 · start 2003-02

    Registered record
    Registry ID
    NCT01228357
    Conditions
    Depression; Depressive Symptoms
    Interventions
    SSRI treated group; non-SSRI treated group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2003-02
    Completion
    2018-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Depressive Symptoms
    InterventionSSRI treated group; non-SSRI treated group
    PhaseNot applicable
    Registry statusUnknown

  • A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions

    NCT00865384 · start 2001-09

    Registered record
    Registry ID
    NCT00865384
    Conditions
    Healthy
    Interventions
    Mirtazapine 15 mg tablets, single dose; REMERON® 15 mg tablets, single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-09
    Completion
    2001-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMirtazapine 15 mg tablets, single dose; REMERON® 15 mg tablets, single dose
    PhasePhase 1
    Registry statusCompleted